KOE · 115450.KQ
HLB Therapeutics Co.,Ltd.
₩2,505-₩55 (-2.15%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.78% below the high.
Loading market information…
KOE · 353810.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:24 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
EASY BIO,Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
EASY BIO,Inc.’s forward annual dividend is ₩250 per share, paid annual. The forward yield is 4.76% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
EASY BIO,Inc.’s next earnings report is currently expected on Nov 18, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow EASY BIO,Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in 2020 and headquartered in Seoul, South Korea, EASY BIO, Inc. offers expert solutions, including specialized feed and dietary supplements, for piglets to customers throughout South Korea and on a global scale.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₩117.6B0.0% vs estimate |
| Q3 2024 | Nov 14, 2024 | ₩183 | ₩106.4B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩2,505-₩55 (-2.15%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.78% below the high.
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
₩13,420-₩660 (-4.69%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
₩10,860-₩90 (-0.82%)
Macrogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.04% below the high.
₩3,000+₩30 (+1.01%)
MedPacto, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.32% below the high.
₩2,165₩0 (0.0%)
Genexine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.09% below the high.
₩915+₩9 (+0.99%)
Amicogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.8% below the high.
₩4,695-₩165 (-3.4%)
Encell Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 77.59% below the high.
